Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827469) titled 'Tofacitinib in the Treatment of IgG4 Related Diseases' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking University People's Hospital
Condition:
Immunoglobulin G4-Related Disease
Janus Kinase Inhibitors
Intervention:
Drug: Tofacitinib 5mg Oral Tablet
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: April 1, 2023
Target Sample Size: 58
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07827469
...